The head of Rare Diseases US at UCB talked about the company’s latest data on rozanolixizumab and zilucoplan in patients living with generalized myasthenia gravis. [WATCH TIME: 3 minutes]
Kimberly Moran, PhD, MBA
Advertisement
Head of Rare Diseases US at UCB.
Articles by Kimberly Moran, PhD, MBA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Alexander Gold, MD, on Adrabetadex’s Impact in Infantile-Onset Niemann-Pick C
2
NeurologyLive® Brain Games: November 2, 2025
3
Showcasing Sustained Benefits in Myasthenia Gravis Research at AANEM 2025: Kimberly Moran, PhD, MBA
4
Designing the Phase 3 EMPEROR Trial and Future Considerations
5
